Hikma Outlines Injectables Growth Amid Slow Start For Generics
Generics Revenues Expected To Be Weighted Towards Second Half Of 2022
Hikma has set out fresh growth forecasts for its injectables business after completing its acquisition of Custopharm. Meanwhile, a slow start to the year for the firm’s generics business amid a “challenging pricing environment” is expected to be followed by higher revenues towards the end of the year.
